【英文論文】

1. Narayanaswami P, Sanders DB, Wolfe GI, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021; 96: 114-122 [IF 9.910]
2. Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: Interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 2021 Mar 16; 14: 1-13. doi: 10.1177/17562864211001995 [IF 6.570]
   
3. Higashi E, Matsumoto S, Nakahara I, Hatano T, Ishii A, Sadamasa N, Ohta T, Ishihara T, Tokunaga K, Ando M, Chihara H, Furuta K, Hashimoto T, Tanaka K, Sonoda K, Koge J, Takita W, Hashikawa T, Funakoshi Y, Kondo D, Kamata T, Tsujimoto A, Matsushita T, Murai H, Matsuo K, Kitazono T, Kira J. Clopidogrel response predicts thromboembolic events associated with coil embolization of unruptured intracranial aneurysms: A prospective cohort study.. PLoS One 2021;16: e0249766. doi: 10.1371/journal.pone.0249766 [IF 3.240]
4. Howard JF, Vissing J, Gilhus NE, Leite MI, Utsugisawa K, Duda PW, Farzaneh-Far R, Murai H, Wiendl H: Zilucoplan: an investigational complement C5 inhibitor for the treatment of acetylcholine receptor autoantibody- positive generalized myasthenia gravis. Expert Opin Investig Drugs. 2021 May; 30: 483-493. doi: 10.1080/13543784.2021.1897567 [IF 6.206]
5. Howard JF, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R, ADAPT Investigator Study Group: Efficacy, Safety, and Tolerability of Efgartigimod in Patients with Generalized Myasthenia Gravis (gMG): Analysis of the Randomized Phase 3 ADAPT Study. Lancet Neurology 2021; 20: 526-536. doi: 10.1016/s1474-4422(21)00159-9 [IF 44.182]
   
6. Berrih-Aknin S, Claeys KG, Law N, Mantegazza R, Murai H, Saccà F, Dewilde S, Janssen MF, Bagshaw E, Kousoulakou H, Larkin M, Beauchamp J, Leighton T, Paci S: The patient-reported impact of myasthenia gravis in the real world: protocol for a digital observational study (MyRealWorld MG). BMJ Open 2021; 11: e048198. doi: 10.1136/bmjopen-2020-048198 [IF 2.692]
7. Shimogawa T, Mukae N, Morioka T, Tanaka S, Sakata A, Uehara T, Mizoguchi M: Possible relationship between vagus nerve stimulation and ictal discharges revealed by long-term electroencephalographic and electrocorticographic monitoring in a non-responsive patient. Interdiscip Neurosurg 2021; 24: 101066. doi: 10.1016/j.inat.2020.101066 [IF 0.090]
8. Uehara T, Shigeto H, Mukaino T, Yokoyama J, Okadome T, Yamasaki R, Ogata K, Mukae N, Sakata A, Tobimatsu S, Kira JI: Rapidly spreading seizures arise from large-scale functional brain networks in focal epilepsy. Neuroimage 2021 Aug 15; 237: 118104. doi: 10.1016/j.neuroimage.2021.118104 [IF 6.556]
9. Takeda A, Yamada E, Uehara T, Ogata K, Okamoto T, Tobimatsu S: Data-point-wise spatiotemporal mapping of human ventral visual areas: Use of spatial frequency/luminance-modulated chromatic faces. Neuroimage 2021 Oct 1; 239: 118325. doi: 10.1016/j.neuroimage.2021.118325 [IF 6.556]
10. Hagiwara K, Okadome T, Mukaino T, Uehara T, Tanaka H, Kamada T, Miyoshi A, Akamatsu N, Ohara S, Shigeto H: Ictal asystole as a manifestation of pure insular epilepsy. Seizure 2021 Oct; 91: 192-195. doi: 10.1016/j.seizure.2021.06.026 [IF 3.184]
11. Mukae N, Shimogawa T, Sakata A, Uehara T, Shigeto H, Yoshimoto K, Morioka T: Reflection of the ictal electrocorticographic discharges confined to the medial temporal lobe to the scalp-recorded electroencephalogram. Clin EEG Neurosci (in press) [IF 1.843]
    
12. Motoki A, Akamatsu N, Fumuro T, Miyoshi A, Tanaka H, Hagiwara K, Ohara S, Kamada T, Shigeto H, Murai H: Characteristics of Olfactory Dysfunction in Patients with Temporal Lobe Epilepsy. Epilepsy Behav (in press) [IF 2.937]
13. Verschuuren J, Palace J, Murai H, Tannemaat M, Kaminski H, Bril V. Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders. Lancet Neurology (in press) [IF 44.182]